Clinical development

Clinical development is the structured sequence of human trials through which a compound is evaluated for a defined medical use — from first-in-human safety studies to the large controlled trials a regulatory authority requires before approving a drug. It is the formal record of human pharmacology, when one exists.

The process runs in phases. Phase I tests safety and tolerability in small groups of volunteers, establishing how the body handles the compound. Phase II begins probing efficacy in people with the target condition, often while refining the dose. Phase III tests efficacy at scale in randomised, controlled trials — typically double-blind and placebo-controlled — generating the data regulators use to make approval decisions.

Most compounds in this encyclopedia never entered clinical development, or were abandoned before completing it. Their human pharmacology is reconstructed from case reports, observational studies, and self-report. That gap is why evidence ratings on many pages here are low — not because nothing is known, but because what is known comes from weaker designs.

What this design can establish

A completed clinical program can establish that a compound produces a specific effect in a defined population under controlled conditions, and that the effect is distinguishable from placebo. This is the kind of evidence that supports a causal claim: the drug did this, in these people, at these doses, over this period.

Phase I data can establish tolerability boundaries and describe how a compound moves through the body — absorption, distribution, metabolism, excretion. Phase III data can establish efficacy within the narrow terms of the trial protocol: the population enrolled, the doses tested, the outcome measured. These are precise, bounded claims.

What it cannot

Clinical development answers a controlled question, which is by design a narrow one. Trials typically exclude people with comorbidities, co-medications, or demographic characteristics not represented in the enrolled cohort. A Phase III result says nothing about the same compound at a different dose, by a different route, in a recreational context, or after years of use.

Two inferences are easy to draw wrongly. First: that a compound with no clinical record is safe — it is simply untested in the formal sense, which is a different thing. Second: that a compound which failed clinical development for one indication has no real pharmacological activity. A negative trial answers a specific question about efficacy in a specific population; it does not rule out effects at other doses, in other contexts, or for other uses.